THERAPEUTIC FOR HIGH-RISK MYELODYSPLASTIC SYNDROME

摘要

The present invention pertains to a novel treatment method for myelodysplastic syndrome, the method being characterized by the combined use of azacitidine and thiopurine. Specifically, the present invention pertains to a drug for the treatment of myelodysplastic syndrome, the drug being characterized in that: azacitidine is subcutaneously or intravenously administered in a dose of 50-100 mg/m² (body surface area) per day; and thiopurine is orally administered in the form of mercaptopurine hydrate in a dose equivalent to 0.5-2.0 mg/kg (body weight) per day, or is subcutaneously or intravenously administered in the form of mercaptopurine hydrate in a dose equivalent to 2-20 mg/m² (body surface area) per day.